Search

Butamben

Butamben is a local anesthetic in the form of n-butyl-p-aminobenzoate. … The FDA removed all parenteral butamben products from the market, possibly due to the poor solubility of this drug.[A254247,L43942]

Mirdametinib

Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

Avapritinib

[A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal

Hydralazine

[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779] … Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.

1,2-Hexanediol

Rimacalib

Rimacalib has been used in trials studying the treatment of Rheumatoid Arthritis (RA).

Menaquinone 7

Menaquinone 7 is under investigation in clinical trial NCT00402974 (The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children).

Deutetrabenazine

It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844] [A32046]. … Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label].

Enzalutamide

[L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. … [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007.

Levodropropizine

Levodropropizine is under investigation in clinical trial NCT01573663 (A Drug-Drug Interaction Study of Ambroxol and Levodropropizine).